Special Issue

Endometrial Stem/Progenitor Cell Biology: Prospects and Challenges

Message from the Guest Editors

Several types of endometrial stem/progenitor cells have been identified: endometrial mesenchymal stem cells, endometrial epithelial progenitor cells and side population cells comprising a heterogeneous population, predominantly endothelial cells. This Special Issue aims to highlight the challenges in endometrial stem/progenitor cell research, the application of endometrial stem/progenitor cells as a cell-based therapy for treating disorders will be welcomed. Areas to be covered in this Special Issue may include but are not limited to: recent evidence of cell-based therapies utilising endometrial derived mesenchymal stem cells, endometrial epithelial progenitors, topics including endometrial clonal evolution, mutation burden, 3D histoarchitecture, endometrial epithelial organoids and single cell sequencing which may have important relevance to endometrial stem/ progenitor cell biology and application in personalised medicine. Contributions by experts in the field, in the form of original research papers and reviews are most welcome.

Guest Editors

Prof. Caroline E. Gargett

Hudson Institute of Medical Research, The Ritchie Centre, Clayton, Australia

Prof. Dharani Hapangama

Department of Women's and Children's Health, Institute of Translational Medicine, University of Liverpool, Liverpool Women's Hospital, Crown Street, Liverpool L8 7SS, UK

Deadline for manuscript submissions

closed (20 September 2021)



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/56131

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/ jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

